Glenmark Pharmaceuticals, a manufacturer of generic formulation products and API, witnessed a rise in share price on Friday after it has been granted tentative approval by the United States Food & Drug Administration (USFDA) for its Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg.

The company will market this product upon receiving final approval of its Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg ANDA.

Lacosamide tablets are the generic version of Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB, Inc.

According to IMS Health sales data for the 12 month period ending September 2015, the Vimpat market achieved annual sales of approximately USD 691.0 million.

Shares of Glenmark Pharmaceutical are trading at Rs 983.50, up Rs 39.75, or 4.21% at the Bombay Stock Exchange (BSE) on Friday at 12:09 p.m.

Total volume of shares traded on the bourses today was higher by 49.62% to 1,182,808 compared with 22-day average volume of 790,557.